Advertisement

Lidocaine Injection

[25 August 2015]

Products Affected - Description

Lidocaine Hydrochloride injection, Amphastar
2%, 5 mL Luer-Jet emergency syringes, 10 count (NDC 76329-3390-01)
 
Lidocaine Hydrochloride injection, AuroMedics
1%, 30 mL vial, 1 count (NDC 55150-0163-30)
2%, 5 mL vial, 10 count, (NDC 55150-0165-05)
 
Lidocaine Hydrochloride injection, Fresenius Kabi
1%, 2 mL vial, 25 count (NDC 63323-0201-02)
1%, 10 mL vial, 25 count (NDC 63323-0201-10)
2%, 2 mL vial, 25 count (NDC 63323-0202-02)
2%, 5 mL SD Tear Top vial, preservative-free, 25 count (NDC 63323-0208-05)
 
Lidocaine Hydrochloride injection, Hospira
1%, 2 mL preservative-free glass ampule, 50 count (NDC 00409-4713-32)
1.5%, 20 mL sterile pack, glass ampule, preservative-free, 5 count (NDC 00409-4056-01)
2%, 2 mL glass ampule, preservative-free, 25 count (NDC 00409-4282-01)
2%, 5 mL vial, preservative-free, 10 count (NDC 00409-2066-05)
 
Xylocaine-MPF injection, Fresenius Kabi
2%, 5 mL vial, 25 count (NDC 63323-0495-07)

Reason for the Shortage

  • Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
  • AuroMedics introduced lidocaine injection in February 2014.
  • Fresenius Kabi has Xylocaine and lidocaine presentations on shortage due to increased demand for the product.
  • Hospira has lidocaine presentations on shortage due to manufacturing delays and increased demand.

Available Products

Lidocaine Hydrochloride injection, AuroMedics
1%, 2 mL ampule, 10 count (NDC 55150-0158-72)
1%, 2 mL vial, 10 count (NDC 55150-0161-02)
1%, 5 mL ampule, 10 count (NDC 55150-0159-74)
1%, 5 mL vial, 10 count (NDC 55150-0162-05)
2%, 2 mL ampule, 10 count (NDC 55150-0160-72)
2%, 2 mL vial, 10 count (NDC 55150-0164-02)

Lidocaine Hydrochloride injection, Hospira
0.5%, 50 mL SD Tear Top preservative-free vial, 25 count (NDC 00409-4278-01)
0.5%, 50 mL SD Flip Top vial, 25 count (NDC 00409-4275-01)
1%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-9137-05)
1%, 5 mL LifeShield syringe, 10 count (NDC 00409-4904-34)
1%, 5 mL preservative-free glass ampule, 50 count (NDC 00409-4713-02)
1%, 20 mL vial, 25 count (NDC 00409-4276-01)
1%, 30 mL sterile-pack preservative-free vial, 25 count (NDC 00409-4270-01)
1%, 30 mL preservative-free vial, 25 count (NDC 00409-4279-02)
1%, 50 mL vial, 25 count (NDC 00409-4276-02)
1.5%, 20 mL preservative-free ampule, 25 count (NDC 00409-4776-01)
2%, 5 mL emergency Ansyr syringe, 10 count (NDC 00409-1323-05)
2%, 5 mL LifeShield syringe, 10 count (NDC 00409-4903-34)
2%, 10 mL preservative-free glass ampule, 25 count (NDC 00409-4282-02)
2%, 20 mL vial, 25 count (NDC 00409-4277-01)
2%, 50 mL vial, 25 count (NDC 00409-4277-02)
4%, 5 mL preservative-free glass ampule, 25 count (NDC 00409-4283-01)

Xylocaine-MPF injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0491-57)
1%, 2 mL vial, 25 count (NDC 63323-0492-27)
1%, 5 mL vial, 25 count (NDC 63323-0492-57)
1%, 30 mL vial, 25 count (NDC 63323-0492-37)
1%, 30 mL vial, sterile pack, 5 count (NDC 63323-0492-31)
1.5%, 10 mL ampule, 5 count (NDC 63323-0493-97)
1.5%, 20 mL ampule, 5 count (NDC 63323-0493-91)
2%, 2 mL vial, 25 count (NDC 63323-0495-27)
2%, 10 mL ampule, 5 count (NDC 63323-0496-97)

Xylocaine injection, Fresenius Kabi
0.5%, 50 mL vial, 25 count (NDC 63323-0484-57)
1%, 20 mL vial, 25 count (NDC 63323-0485-27)
1%, 50 mL vial, 25 count (NDC 63323-0485-57)
2%, 10 mL vial, 25 count (NDC 63323-0486-17)
2%, 20 mL vial, 25 count (NDC 63323-0486-27)
2%, 50 mL vial, 25 count (NDC 63323-0486-57)

Estimated Resupply Dates

  • Amphastar has 2% lidocaine 5 mL syringes on intermittent back order and the company is regularly releasing product.
  • AuroMedics has 1% lidocaine 30 mL vials available with short expiration dating (February 2016). AuroMedics has 2% lidocaine 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Fresenius Kabi has 1% lidocaine 2 mL and 10 mL vials on back order and the company estimates a release date of late-October 2015 for the 2 mL vials and early-October 2015 for the 10 mL vials. The 2% lidocaine 2 mL vials are on back order and the company estimates a release date of early-October 2015. The 2% lidocaine 5 mL preservative-free vials are on intermittent back order and the company is releasing product as it becomes available. The 2% Xylocaine-MPF 5 mL vials are on intermittent back order and the company is releasing product as it becomes available.
  • Hospira has lidocaine 1.5% 20 mL ampules, preservative-free, in sterile pack on back order and the company cannot estimate a release date. The 1% lidocaine 2 mL preservative-free ampules are on back order and the company estimates a release date of mid-September 2015. The 2% lidocaine 2 mL preservative-free vials and 5 mL vials are on back order and the company estimates a release date of early-September 2015.

Related Shortages

Updated

August 25, July 10, June 2, 23, and 25, May 1, April 9, March 4 and 23, February 3, 17, and 25, January 26 and 29, 2015; December 4 and 18, November 20, October 1 and 14, September 4, 8, and 15, August 4 and 28, July 11, June 12, 26, 30, May 7 and 22, April 7 and15, March 7 and 28, February 7, 21, and 24, 2014; January 9, 2014; December 5 and 18, November 5, 11, and 20, October 2 and 17, 2, September 13, August 8 and 28, July 2, 11, and 25, June 13 and 27, May 9 and 28, April 10, March 13, February 6, January 17, 2013; December 12, October 25, September 27, August 9 and 22, July 26, June 12 and 21, May 2 and 23, April 16 and 18, March 7, 20, 28, February 8 and 22, January 3 and 25, 2012; December 5 and 16, November 16, 2011, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement